About the Authors

Aaron S. Kesselheim

akesselheim@partners.org

Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

AK reports serving on an external advisory board in 2012 for the non-profit group Community Catalyst related to patient education about generic drugs, and serves as a consultant to the non-profit Alosa Foundation (not affiliated with any pharmaceutical company) in its academic detailing work, for which he receives a nominal payment. AK also reports acting as an expert witness for the law firm Hagens Berman Sobol & Shapiro on behalf of classes of individual plaintiffs and pharmaceutical wholesalers in two cases: one alleging inappropriate marketing tactics against AstraZeneca (2011–2012) and another alleging delayed bioequivalent generic drug entry against Warner Chilcott (2013). AK has received grants in 2012–2013 from the Pew Charitable Trusts relating to medical device regulation and off-label drug marketing. AK is a member of the Editorial Board of PLOS Medicine.

Author Contributions

Wrote the first draft of the manuscript: AK. Contributed to the writing of the manuscript: AK. ICMJE criteria for authorship read and met: AK. Agree with manuscript results and conclusions: AK.